Navigation Links
Torbjorn Bjerke Appointed as new CEO for Karolinska Development
Date:8/23/2010

Torbjorn Bjerke Appointed as new CEO for Karolinska Development -- STOCKHOLM, August 23, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements Click to view news release full screen  

Torbjorn Bjerke Appointed as new CEO for Karolinska Development

 

STOCKHOLM, August 23, 2010 /PRNewswire/ -- Torbjorn Bjerke has been appointed as new CEO for Karolinska Development. He is currently CEO for Orexo, a position he has held since 2007. Torbjorn Bjerke succeeds Conny Bogentoft who will assume the position as Chief Scientific Officer for Karolinska Development.

Starting its operation in 2003, Karolinska Development has rapidly become one of the leading companies within early pharmaceutical development in Europe. Investments by Karolinska Development have focused on developing its portfolio companies to proof of concept. Karolinska Development has now entered a next phase where the company will seek external partners for some of its portfolio companies while preparing for an initial public offering.

"With his solid background as a commercial leader, Torbjorn Bjerke has the right profile for the role as CEO for Karolinska Development. He has vast experience from leading and developing early research-based companies as well as a listed pharmaceutical company. Torbjorn's experience in business development and his demonstrated ability in negotiating and implementing collaborations with international partners will be of great value to us, our shareholders and our portfolio companies," says Hans Wigzell, Chairman of Karolinska Development.

Torbjorn Bjerke has held the position as CEO for Orexo since 2007. He will assume the position as CEO for Karolinska Development when his successor has been appointed. Conny Bogentoft, who has held the position as CEO for Karolinska Development since its inception in 2003, will become Chief Scientific Officer with overall responsibility for the future development of Karolinska Development's portfolio.

"I look forward to my new role as CEO for Karolinska Development, and to lead one of the most exciting pharmaceutical companies in Europe to further success and a future IPO," says Torbjorn Bjerke.

TO THE EDITORS

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com

For further information, please contact: Hans Wigzell, Chairman of the board, Karolinska Development Tel: +46(0)705-76-05-39, e-mail: hans.wigzell@ki.se Conny Bogentoft, CEO, Karolinska Development Tel: +46(0)706-88-61-43, e-mail: conny.bogentoft@karolinskadevelopment.com Torbjorn Bjerke, appointed CEO, Karolinska Development Tel: +46(0)708-66-19-90, e-mail: info@karolinskadevelopment.com
'/>"/>

SOURCE Karolinska Development AB PUBL
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shawn Cross Appointed CEO of Burrill Merchant Banking Group
2. New President and CEO appointed at Ocean Nutrition Canada Limited
3. Professor Sander van Deventer Appointed to Supervisory Board of AMT
4. New Board Director Appointed
5. China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor
6. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
7. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
8. Lori Kahler Appointed President of The RC Insight Group
9. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
10. FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
11. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery ... announced today the appointment of a new Chairman, Mr ... Carmine , effective immediately. James Garner , ... Executive Director and former Acting CEO, Mr Iain Ross ... Non-Executive Director. --> James Garner , has also ...
(Date:2/4/2016)... Falls Church, VA (PRWEB) , ... ... ... a first-year cybersecurity conference presented by Bloomsburg University’s Digital Forensics Club, takes ... Bloomsburg, PA. The two-day event features 20+ speakers and activities such as ...
(Date:2/4/2016)... ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... be held February 8-9, 2016, at the Waldorf Astoria ... & Healthcare Conference, taking place in New ... James Sapirstein , Chief Executive Officer of ContraVir, will ...
(Date:2/4/2016)... ... , ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz ... from other cuvette manufacturers is their supercharged customer service and their extensive database of ... steady flow of inside information, they have recently revamped their manufacturing techniques to reduce ...
Breaking Biology Technology:
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2, 2016   Parabon NanoLabs (Parabon) ... Army Research Office and the Defense Forensics and ... of the company,s Snapshot Kinship Inference ... more generally, defense-related DNA forensics.  Although Snapshot is ... appearance and ancestry from DNA evidence), it also ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
Breaking Biology News(10 mins):